GlassScriptPhysician profile
Patrice Ihry
NPI 1083018220
$3,972.23
in general payments reported to CMS, 2019-2025
27 companies · $1,034 in 2025
The $1,034 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $421 · 2022: $357 · 2023: $663 · 2024: $1,498 · 2025: $1,034.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,181 · Education: $14.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,180.64 |
| Education | $14.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $674.02 | 2023-2025 | Voquezna |
| Abbvie INC. | $545.22 | 2021-2025 | |
| Genzyme Corporation | $511.27 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $252.75 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Enterra Medical, INC. | $230.16 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $228.52 | 2022-2023 | Zeposia |
| Medtronic, INC. | $217.45 | 2023-2024 | Gi Genius, Interstim |
| Celgene Corporation | $201.85 | 2021-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $153.95 | 2021-2024 | Dificid |
| Regeneron Healthcare Solutions, INC. | $148.33 | 2023-2024 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $125.89 | 2021-2023 | Trulance |
| Lilly USA, LLC | $103.62 | 2024 | Omvoh |
| Organon LLC | $85.52 | 2022-2025 | Hadlima, Renflexis |
| Ferring Pharmaceuticals INC. | $83.47 | 2022-2024 | Rebyota |
| Aimmune Therapeutics, INC. | $67.57 | 2025 | Zenpep, Vowst |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $57.96 | 2021-2025 | Uplizna |
| Redhill Biopharma INC. | $48.98 | 2021 | |
| Ardelyx, INC. | $46.87 | 2023-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $31.51 | 2021-2025 | |
| Johnson & Johnson Health Care Systems INC. | $30.20 | 2022 | |
| Nestle Healthcare Nutrition INC. | $27.81 | 2022-2023 | |
| Janssen Biotech, INC. | $22.96 | 2025 | Tremfya |
| Pfizer INC. | $17.65 | 2023 | |
| Novo Nordisk INC | $15.50 | 2025 | Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.34 | 2025 | Caplyta |
| Qol Medical, LLC | $14.51 | 2021 | |
| Madrigal Pharmaceuticals | $13.35 | 2024 | Resmetirom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrice Ihry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.